SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

414

Participants

Timeline

Start Date

January 4, 2011

Primary Completion Date

July 22, 2016

Study Completion Date

July 22, 2016

Conditions
MDSCMMLAML
Interventions
DRUG

Guadecitabine

Subcutaneous injection

Trial Locations (16)

10021

Cornell University, New York

10032

Columbia University Medical Center, New York

14263

Roswell Park Cancer Institute, Buffalo

19111

Temple University, Philadelphia

27705

Duke University, Durham

33705

Florida Cancer Specialists - North, St. Petersburg

33916

Florida Cancer Specialists - South, Fort Myers

37203

Sarah Cannon Research Institute, Nashville

Tennessee Oncology, Nashville

43210

Ohio State University, Columbus

60637

University of Chicago Cancer Center, Chicago

77030

MD Anderson Cancer Center, Houston

85259

Mayo Clinic, Scottsdale

90033

University of Southern California, Los Angeles

06520

Yale University, New Haven

M5G 2M9

Princess Margaret Hospital, Toronto

Sponsors
All Listed Sponsors
lead

Astex Pharmaceuticals, Inc.

INDUSTRY